Azetidine-Substituted Crystal Forms for KRAS G12C Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing KRAS G12C mutation-targeting inhibitors face challenges with low enzyme activity, poor metabolic stability, and limited cellular antiproliferative activity, making them ineffective in treating cancers with KRAS G12C mutations.
Innovation Solution
Development of crystal forms of a specific azetidine-substituted compound with characteristic X-ray powder diffraction peaks, exhibiting good cellular activity, selectivity, and stability, suitable for use in medicaments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing KRAS G12C mutation-targeting inhibitors are used, then they can bind to the KRAS G12C mutant protein, but they exhibit low enzyme activity and poor metabolic stability
Solution Approach 1:
The patent modifies the chemical structure of the inhibitor by introducing an azetidine substituent at specific positions (such as the 4-position of the pyridine ring or the 2-position of the phenyl ring), which changes the physical and chemical parameters of the molecule. This structural modification leads to improved metabolic stability while maintaining or enhancing enzyme binding activity, thereby resolving the contradiction between enzyme activity and metabolic stability.
Solution Approach 2:
The patent creates a composite molecular structure by combining multiple functional groups (pyridine ring, phenyl ring, azetidine substituent, and acrylamide fragment) into a single inhibitor molecule. This composite structure allows the molecule to simultaneously achieve high enzyme binding affinity through the acrylamide fragment and improved metabolic stability through the azetidine-substituted core structure, thus resolving the technical contradiction.
2Reliability
If existing KRAS G12C inhibitors are developed, then they show some cellular antiproliferative activity, but the activity is limited and metabolic stability is poor
Solution Approach 1:
The patent optimizes the molecular parameters by adjusting the substituent groups and their positions on the core structure. The azetidine substituent specifically enhances both the cellular antiproliferative activity (by improving cell permeability and target engagement) and the metabolic stability (by protecting against enzymatic degradation), thereby simultaneously improving both parameters that were previously in contradiction.
3Stability of the object's composition
If crystal forms of the azetidine-substituted compound are prepared, then metabolic stability and solubility are enhanced, but the process requires specific crystallization conditions
Solution Approach 1:
The patent utilizes phase transition principles by controlling the crystallization process from solution to solid state. By selecting appropriate solvents and temperature conditions, the compound is induced to form stable crystal forms with enhanced metabolic stability and solubility. The specific crystallization conditions (such as solvent selection and temperature control) are optimized to achieve the desired crystal form while maintaining ease of manufacture through a straightforward crystallization protocol.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms of the azetidine-substituted compound demonstrate enhanced metabolic stability, solubility, and druggability, providing effective treatment options for various cancers, including lung cancer, lymphoma, and others.
Implementation Method 1
an X-ray powder diffraction pattern of which has characteristic diffraction peaks at the following 2θ angles: 5.89±0.20°, 8.82±0.20°, and 17.71±0.20°
Data Source
AI summary
A crystal form of an azetidine-substituted compound as represented by formula (I) and a preparation method therefor. Further comprised is an application of the crystal form in preparing a drug for treating cancer.